Stronger outlook in Apple upgrade cycle andLeoni/ODM synergies; Lift TP to RMB75.55

立讯精密(002475)
    We raise TP to RMB75.55 (25% upside) to reflect our more positive view oniPhone 17/ foldable cycle, stronger synergy from Leoni/ODM integration, and AIserver component pipeline (connectivity/thermal/power). We raise FY25-27EEPS by 0-19% to reflect FY25 guidance, enhanced synergy and better margin.We expect Luxshare to deliver 27% earnings CAGR over 2025-27E, driven by9%/54%/47% FY25-27E revenue CAGR from consumer electronics/automotive/communication segments. Trading at 25x/20x FY25/26E P/E after recentpullback, valuation is attractive in our view. Upcoming catalysts include iPhone17 shipment, auto client wins, and AI server component ramp-up.
    Beneficiary of Apple multi-product upgrade cycle. With a full coverageof Apple’s products (iPhone/Watch/AirPods/Mac/VisionPro), we believeLuxshare is well-positioned to benefit from strong execution and marketshare gains from Apple’s new product cycle in iPhone 17/foldable/20thanniversary edition and smart home/AI glasses during 2026-27E
    Synergies from consolidation of Leoni and Wingtech's ODM. Mgmt.highlighted that the integration process has exceeded expectations: 1)original targets for Leoni (e.g. NP breakeven in 2025, GPM to reach corp.avg.) will be achieved at least one year earlier, and 2) vertical integrationwith Wingtech ODM will enhance competitiveness and boost exposure tonon-Apple biz, particularly in PC segment targeting doubled sales over nextthree years.
    Strong AI server product pipeline. We believe Luxshare is makingprogress with design wins and share gains with core AI server products(high-speed connectivity/power/thermal). In particular, mgmt. remainsconfident that CPC will become mainstream connectivity solution in nearterm, and AC/DC products have achieved breakthrough with corecustomers.
    Upbeat FY25E guidance on iPhone 17 and better GPM. Luxshare guidedFY25E NP growth of 24-29% YoY, mainly driven by new iPhone models andbetter profitability from Leoni and Wingtech assets. 3Q25 GPM at 12.8%(+1.1ppt YoY/0.8ppt QoQ) was a positive surprise, thanks to higher-marginauto/communications segments and strong execution of new acquisitions.
    Multiple growth engines to drive re-rating; Raise TP to RMB75.55 Webelieve revenue mix shift to higher-growth, high-margin AI/auto segmentsalong with stronger Apple upgrade cycle will boost re-rating. We raise ourTP to RMB75.55, based on 10-year hist. avg. 25x FY26E P/E (vs prior 21x)for Apple cycle strength and strong execution of Leoni/ODM integrations.

AI需求推动季度业绩创新高；云厂商资本支出强劲，展望积极

中际旭创(300308)
    中际旭创季度业绩再次创下新高，公司三季度收入达102亿元人民币，同、环比分别增长57%、26%。受益于800G光模块出货带来的规模效应，以及硅光解决方案采用率提升，毛利率大幅提升至42.8%，较去年同期和上季度分别上升9.2、1.3个百分点。净利润激增至31亿元人民币，创历史新高，同、环比分别增长125%、30%。净利率提升至30.7%（去年同期和上季度分别21.4%和29.7%）。重申“买入”评级，目标价上调至591元人民币。
    800G出货强劲，叠加硅光技术渗透率提升共同推动毛利率创下新高，主要得益于产品结构的优化：800G光模块需求持续增长、1.6T产能稳步增加。同时，硅光技术在成本结构方面有优势，而硅光解决方案在800G和1.6T产品中的渗透率进一步提升，也推动利润率的持续向好。另外，生产良率的改善和效率的提升也推动利润率的上行。展望未来，管理层预计800G光模块的增长势头将继续，1.6T硅光产品预计在2026年初进入大规模量产阶段。
    公司的行业龙头地位将有效缓解原材料供应危机。管理层确认，自2024年以来，EML和CWL等关键上游元器件的供应持续紧张，但公司在全球光模块市场的龙头地位有望确保其原材料的供应。公司已提前与主要供应商锁定长期产能，以降低潜在的供应链风险。管理层预计，随着上游制造商产能的逐步扩张，当下的供应链瓶颈有望在明年上半年逐步得到缓解。
    大型云厂商对人工智能基础设施的资本支出扩张，确认了公司在中短期的增长前景。海外主要大型云厂商正持续加大对人工智能基础设施的投资，这为公司带来了强劲的需求红利。谷歌于近期上调了2025财年资本支出指引，从此前的850亿美元增加至910-930亿美元。Meta将其2025财年目标缩窄至700-720亿美元的区间高位。微软表示，虽然此前预期明年投资增速可能放缓，但目前看资本支出将继续扩张。这些大型云厂商对人工智能基础设施的持续投资，有望在未来推动公司销售额的进一步增长。
    重申"买入"评级，目标价上调至591元人民币，基于28倍2026年预测市盈率，高出5年历史平均市盈率1个标准差，主要是考虑到本轮强劲的云厂商资本开支扩展周期，以及公司在光模块市场上的领导地位。我们将公司2026年净利润预测上调52%，反映下游资本支出拉动公司收入预期的提升。主要风险：人工智能资本支出不及预期、地缘政治和关税的不确定性、供应链风险以及市场竞争加剧等。

三季度业绩表明AI周期全面启动，目标价上调至90元人民币

生益科技(600183)
    生益科技发布了强劲的2025年三季度业绩。公司收入达79亿元人民币（同/环比增长55%/12%），毛利率大幅提升至28.1%（去年同期/上季度分别为22.9%/26.9%）。净利润同/环比大幅增长131%/18%至10亿元人民币，推动净利率提升至12.8%（去年同期/上季度分别为8.6%/12.2%）。出色的业绩凸显了公司作为AI基础设施核心供应商的战略地位。我们预计公司2025/26年收入将同比增长41%/38%，净利润同比增长102%/79%。重申"买入"评级，目标价上调至90元人民币（基于2026年估值），上调盈利预测以反映公司在AI驱动下的强劲增长势头（本次为更强劲的上升周期）和利润率的持续改善。
    印制电路板：受益于AI服务器的强劲需求。子公司生益电子（688183CH，未评级）业绩创单季度新高，印刷电路板收入达31亿元人民币（同/环比增长154%/40%）。季度收入接近2023年全年水平（33亿元人民币），凸显了AI服务器市场对高层数HDI板的强劲需求。我们看到主要大型云厂商持续加大对AI基础设施的投资。作为AI供应链的主要受益者，我们预测生益电子全年印刷电路板收入将接近100亿元人民币（增长逾一倍），成为集团主要的增长引擎。
    覆铜板：在成本压力下稳健前行。覆铜板业务（含其他）实现收入49亿元人民币（同比增长23%，环比持平）。虽然面临铜价上涨（自7月以来伦敦金属交易所铜价上涨15%）带来的短期压力，但我们预计平均售价的上调将抵消成本通胀的大部分影响。我们预测2025年公司覆铜板收入将增长18%，并带动公司收入增长约41%。
    利润率：产品组合优化推动利润率的结构性提升。2025年前三季度，集团毛利率分别环比上升2.5/2.3/1.3个百分点，在三季度达到28.1%。这反映印刷电路板业务向高价值HDI产品的快速转变（生益电子三季度毛利率：33.9%，同/环比上升9.0/3.1个百分点）。我们预计随着潜在的价格调整，四季度利润率有望进一步改善，预计2025年公司毛利率为27.3%。
    重申"买入"评级，目标价上调至90元人民币，基于35倍2026年预测市盈率（此前为30倍2025年市盈率），接近其5年历史远期市盈率2个标准差以上的水平，主要由于：1）公司在AI上升周期中的结构性定位；2）印刷电路板业务盈利贡献的持续增长以及其相较覆铜板业务的估值溢价。我们将2025/26年收入预测上调1%/16%，净利润预测上调5%/46%，以反映公司强劲的增长和显著的利润率改善。主要风险包括：产能爬坡不及预期、市场竞争加剧、地缘政治风险升级等。

Record-high quarter driven by AI demand; Robust cloud capex underpins outlook

中际旭创(300308)
    Innolight delivered yet another record-breaking quarter,with revenue rising+57%/+26%YoY/QoQ to RMB10.2bn.Gross margin expanded sharply by+9.2/+1.3ppt YoY/QoQ to42.8%,driven by strong leverage from800Gtransceiver shipments and broader uptake of SiPh-based solutions.Net profitsurged+125%YoY/+30%QoQ to RMB3.1bn,also a record high,with netmargin reaching30.7%(vs.29.7%in2Q25and21.4%in3Q24).ReiterateBUY,with TP raised to RMB591.
    Strong800G shipments and rising SiPh adoption underpin record-high GPM.GPM expansion was mainly driven by a richer product mix,ledby sustained800G volume growth and the ramp of1.6T transceivers.Thebroader adoption of SiPh across both800G and1.6T product lines furtherlifted margins,given its inherently more favorable cost structure.Continuedyield improvement and higher production efficiency also contributed tomargin gains.Mgmt.expects800G momentum to remain solid,while1.6TSiPh transceivers are set to enter mass production in early-2026.
    Raw material tightness manageable given market leadership.Mgmt.acknowledged ongoing tightness in key upstream opticalcomponents such as EML and CWL since2024,but noted the company’sleading position in the global optical transceiver market enables it to securesufficient material supply for production needs.The company hasproactively locked in long-term capacity with major suppliers to mitigatepotential disruptions.Mgmt.expects the current supply constraints togradually ease by1H26as upstream manufacturers expand productioncapacity.
    Hyperscalers’expanding AI infrastructure capex reinforces near-tomedium-term growth for the company.Major overseas hyperscalerscontinue to scale investment in AI infrastructure,providing a strong demandtailwind for Innolight.Google recently guided CY25E capex of US$91–93bn(vs.US$85bn previously),while Meta raised its CY25E target to US$70-72bn.Microsoft also reiterated that capex will continue to grow despiteearlier expectations of moderation.This sustained hyperscaler spendingmomentum will further support the company’s sales in the coming quarters.
    Reiterate BUY,with TP raised to RMB591,based on28x2026E P/E,1SDabove5-year historical avg.P/E,justified by Innolight’s leadership in AIoptical transceivers market during this strong investment cycle.Our NPforecast for2026E is revised up by52%,reflecting higher revenueexpectations due to increasing capex.Key risks include lower-than-expected AI capex,geopolitical/tariff uncertainties,supply chain disruptionsand intensified competition,etc.

Overseas strength offsets domestic softness

迈瑞医疗(300760)
    Mindray reported9M25revenue of RMB25.8bn,down by12.4%YoY.Revenuein3Q25reached RMB9.1bn,up by1.5%YoY,indicating a turnaround driven byaccelerating overseas growth and mild domestic recovery.Overseas revenuerose12%YoY to RMB4.6bn in3Q,with revenue from Europe up by29%.Domestic revenue fell by7%YoY in3Q,while the decline narrowed notablycompared to1H25.We anticipate a further acceleration in growth in4Q25,supported by the ongoing recovery in domestic equipment procurement,solidoverseas momentum,and a favorable base effect.
    IVD:solid overseas growth;accelerated TLA installation.In3Q25,IVDsegment reported revenue of RMB3.6bn,down by3%YoY,with overseasIVD revenue achieving double-digit growth.TLA(Total LaboratoryAutomation)installations continued to accelerate.In9M25,180units of theMT8000TLA were installed in China,and full-year domestic deploymentsare expected to exceed200units,per company guidance.OverseasMT8000sales surpassed20units,which has met the full-year target.Weexpect TLA systems to enhance Mindray’s penetration into leading domestichospitals and medium-to-high throughput labs overseas,supporting long-term IVD growth.
    MIS:continued high-end upgrade.MIS segment reported revenue ofRMB1.7bn in3Q25,roughly flat YoY.Overseas MIS grew at a high single-digit rate,while sales of ultra-high-end products doubled in9M25.We seesignificant potential for market share gains in high-end and ultra-high-endultrasound,both domestically and internationally,driven by the risingadoption of Resona A20/Nuewa A20and upcoming launches in thepremium portfolio.
    Profitability under headwinds.Mindray’s attributable net margin declinedto29.3%in9M25,down7ppts YoY,mainly due to domestic pricing pressurefrom volume-based procurement(VBP)and intensified competition.Increased investment in overseas expansion also led to an increase inselling expenses.Going forward,we expect greater in-house reagent rawmaterial production,a higher mix of high-end products,and growingoverseas contribution to partly offset domestic margin pressure and supportsound long-term profitability.
    Maintain BUY.Given continued demand and pricing pressure in the IVDsegment,we revise down our2025E-27E forecasts and lower our targetprice to RMB249.21based on a9-year DCF model(WACC:9.1%,terminalgrowth:3.0%).

Strong recovery in Q3

联影医疗(688271)
    United Imaging (UIH) reported strong 9M25 results, with revenue of RMB8.9bn(+27% YoY), reaching 69% of our prior full-year estimate and exceeding thehistorical average of ~65%. The sharp 75% YoY revenue growth in 3Q25 wasdriven by a significant recovery in domestic equipment procurement, sustainedoverseas growth momentum, and a low base in 3Q24. Domestic demandremained solid, with the value of medical imaging tenders up by 55% YoY in 3Q25,according to Joinchain. Overseas growth was supported by strong order intakeand improved order-to-revenue conversion. Therefore, we raise our 2025Erevenue forecast to RMB13.3bn, implying 28.8% YoY growth.
    Robust performance of high-end portfolios. UIH’s domestic revenue grew24% YoY to RMB6.9bn in 9M25, driven by procurement recovery and marketshare gain of over 4ppts. High-end products remained a key growth driver. 1)MR revenue grew 40% YoY, with notable share gains in 5T (+ ~52ppts) and3T (+over 4ppts). 2) CT revenue increased 8% YoY with high-end CT up ~30%YoY. We expect photon-counting CT uCT Ultima and uCT Siriux to furtherstrengthen UIH’s position in the high-end CT market. 3) MI revenue rose 22%YoY with PET/CT maintaining its decade-long leading position in China. uMIPanorama has contributed ~40% of MI revenue. 4) XR and RT both delivereddouble-digit growth with continued share gains. The increasing revenuecontribution from mid- to high-end products is expected to offset marginpressures from lower-end portfolios. Moreover, the upcoming launch of acomprehensive ultrasound portfolio in Nov 2025 should further support UIH’s“diagnosis-to-treatment” strategy and high-end imaging leadership, in ourview.
    Overseas business maintained strong momentum. Overseas revenuerose 42% to RMB2.0bn, representing 22.5% (+2.3ppts) of total revenue in9M25. Revenue in North America grew by over 50% YoY to ~RMB700mn in9M, with US service revenue up 80%+ YoY on the back of an expandinginstalled base. A diversified supply chain and proactive inventory managementhelped mitigate tariff pressure, while recurring service revenue may enhancelong-term resilience. European revenue more than doubled YoY to overRMB400mn in 9M. Notably, uMI Panorama GS and uMI Panvivo havepenetrated into the high-end market in Western Europe. Asia-Pacific andemerging markets also delivered double-digit growth. Management indicatedrobust overseas order intake. With stronger sales conversion from orders, weexpect overseas growth to remain solid in 4Q25E.
    Maintain BUY. Considering the rapid domestic recovery in 2025E and strongoverseas growth momentum, we raise our forecasts of 2025–2027E revenueCAGR from 22.6% to 24.1%. Based on a 9-year DCF model (WACC: 8.1%,terminal growth: 4.0%), we raise our target price to RMB162.29

3Q25 results: AI super-cycle in full swing; Raising TP to RMB90

生益科技(600183)
    Shengyi Technology(Shengyi)reported robust3Q25results.Revenue reachedRMB7.9bn(+55%/+12%YoY/QoQ),with gross margin expanding sharply to28.1%(vs.22.9%in3Q24and26.9%in2Q25).Net profit surged131%/18%YoY/QoQ to RMB1.0bn,lifting net margin to12.8%(vs.8.6%/12.2%in3Q24/2Q25).The results underscore Shengyi’s strategic positioning as a coreAI infrastructure play.We expect the Company’s revenue to grow41%/38%YoYin2025/26E,while NP to grow102%/79%YoY.Reiterate BUY and raise our TPto RMB90,as we roll over our valuation period to2026E and raise earningsforecast to reflect strong AI-driven momentum(a much stronger upcycle)andsustained margin improvement.
    PCB:riding the AI server wave.Subsidiary Shengyi Electronics(688183CH,NR)delivered another record quarter,with PCB revenue hittingRMB3.1bn(+154%/+40%YoY/QoQ).Quarterly revenue nearly matched full-year2023level(RMB3.3bn),highlighting strong demand for high-layer countHDI boards used in AI servers.We see major hyperscalers continue to scaleinvestment in AI infrastructure.As a key beneficiary,we forecast ShengyiElectronics’full-year PCB revenue near RMB10bn(more than doubled)thisyear,becoming the group's primary growth engine.
    CCL:steady amid cost headwinds.The CCL segment(incl.other)postedrevenue of RMB4.9bn(+23%YoY,flat QoQ).While elevated copper prices(LME+15%since July)pose near-term pressure,we expect ASP increasesto largely offset cost inflation.We project CCL revenue to grow18%in2025,bringing group revenue growth to~41%.
    Margins:structural upside from mix shift.Group gross margin rose2.5pp/2.3pp/1.3pp through the first three quarters of2025,reaching28.1%in3Q.This reflects the PCB segment's rapid mix shift toward high-value HDIproducts(Shengyi Elec.GPM:33.9%in3Q,+9.0ppt/+3.1ppt YoY/QoQ).Weexpect further improvement in4Q with potential price adjustments,andproject2025group GPM of27.3%.
    Reiterate BUY with TP raised to RMB90,based on35x2026E P/E(vs.prev.30x2025E P/E),near+2SD above its5-yr hist.forward P/E,given1)Shengyi's structural positioning in the AI upcycle,and2)PCB's risingearnings contribution and premium valuation vs.CCL.We raise our revenueforecast by1%/16%for2025/26E and NP forecasts by5%/46%,reflectingthe strong growth and significant margin improvements.Key risks include:slower-than-expected capacity ramp-up,intensified competition,geopoliticaluncertainties,etc.

Rising demand for small molecule D&M business

药明康德(603259)
    WuXi AppTec reported strong 3Q25 results, with revenue increasing by 15.3%YoY (including 19.7% YoY growth for continuing operations) and adj. non-IFRSnet profit surging by 42.0% YoY. Revenue from continuing operations in 9M25accounted for 73.8% of our full-year forecast, in line with historical average of72%, while adj. non-IFRS net profit in 9M25 represented 85.7% of our full-yearforecast, significant higher than the historical average of 72%. WuXi AppTecdelivered strong operational execution, despite ongoing macro uncertainties. Assuch, mgmt. further raised its full-year guidance for 2025, expecting total revenueto be RMB43.5-44.0bn (previously: RMB42.5-43.5bn) with revenue fromcontinuing operations to grow by 17-18% (previously: 13-17%). Mgmt. continuedto expect adj. non-IFRS net profit margin to expand in 2025.
    Encouraging demand growth in small molecule D&M business. As ofSept 2025, WuXi AppTec’s backlog from continuing operations reached RMB59.88bn with a strong YoY growth of 41.2%, accelerated from 37.2% YoY asof Jun 2025. In contrast, backlog for TIDES services grew by 17.1% YoY asat end-Sept 2025, slowing from 48.8% YoY seen as at end-Jun 2025. Thedivergence underscored the small molecule D&M business as a primarygrowth driver for backlog in 3Q25. With that, mgmt. expected acceleratedrevenue growth for this segment in 2026. Mgmt. noted that the Company’spipeline included multiple promising products targeting areas such as GLP-1, PCSK9, pain, neurology, and autoimmune diseases. Given that smallmolecule D&M accounted for 46% of total revenue in 2024, we believe it willbecome a key driver for the Company’s overall growth. To meet the risingcustomer demand, WuXi AppTec is actively expanding manufacturingcapacity in China, Singapore, the US, and Switzerland.
    Early-stage demand showing more signs of recovery, though a fullrebound will take time. In the Chemistry segment, revenue from drugdiscovery services declined 2.0% YoY in 3Q25, though sequential QoQimprovements were seen. Notably, the safety assessment services posted5.9% YoY and 13.2% QoQ revenue growth in 3Q25, a significant reboundfrom the 7.8% decline in 2Q25, suggesting a recovery in client demand andimproved pricing dynamics. Within the Biology segment, revenue grew 5.9%YoY in the quarter, consistent with the pace observed in 1H25. Mgmt.indicated that early signs of demand recovery are emerging, supported by arebound in China’s capital markets, robust global BD activity, and US interestrate cuts. However, a broad-based industry recovery will still take time. Giventhe high sensitivity to macroeconomic conditions, we believe early-stagebusinesses within WuXi AppTec should have relatively high visibility over thenext two years, as market conditions normalize.
    Maintain BUY. We raise our DCF-based TP from RMB118.79 to RMB123.35(WACC: 9.39%, terminal growth: 2.00%; both unchanged), to factor in ourimproved outlook on the macro environment. We now expect revenue to growby 12.8%/ 10.7%/ 14.2% YoY (for continuing operations: 18.0%/ 15.0%/14.2% YoY) and adjusted non-IFRS net profit to grow by 19.6%/ 10.2%/13.3% YoY in 2025E/ 26E/ 27E, respectively.

投资者日：TIDES势头延续，早期研发初现回暖

药明康德(603259)
    药明康德举办了投资者日活动，我们认为此次会议的要点如下：1）TIDES业务发展势头不变，产能扩张迅速、管线储备丰富；2）早期研发显现进一步复苏的信号，将拉动占公司总收入约1/3的早期业务收入的增长；3）精细化运营助力公司在面对宏观不确定性以及进行全球产能扩张的同时保持有韧性的盈利能力。
    产能扩张支持TIDES业务保持发展势头。公司将按计划在25年底将多肽产能扩张至超过10万L，显著高于2024年底的4.1万L。截至25年8月，药明康德TDIES管线包含23个GLP-1类项目，其中16个在临床2/3期，占全球的26%。除了GLP-1类项目，管线内的其他分子例如环肽和核酸项目也已进入商业化或者PPQ阶段，将为TIDES业务带来业绩增量。此外，TIDES业务完美体现了公司“跟随分子”战略，在1H25，TIDES管线中有19个项目从R阶段推进至D阶段，占TIDES业务D阶段1H25新增新分子数的50%。管理层维持TIDES收入全年增长超过80%的指引。管理层目标未来TIDES业务的全球市占率高于传统小分子业务(D阶段~16%市占率)。
    早期研发需求复苏信号进一步显现。国内外早期研发需求均看到积极催化因素。在国内市场，创新药BD热潮以及其引发的资本市场融资复苏，为中国biotech创新研发带来了资金支持。在海外市场，美联储在9月份再次开启降息通道，有望刺激海外biotech融资的复苏。作为全球药物早期研发最大的赋能平台之一，药明康德将会显著受益于全球早期研发需求的复苏。1H25，公司的临床前新签订单同比增长14.5%，其中来自美国客户的新签订单同比增长19.9%。新分子的研发客户需求维持强劲增长，1H25PDC相关DMPK收入同比增长25%，CGT相关生物分析收入增长393%。
    精细化运营提升。公司的CRDMO商业模式以及前瞻的产能建设带来了充足的订单，公司强大的执行能力也保证了订单的交付效率以及利润率。公司的新厂房从投产至满负荷运转所需的时间已从2017年的22.6个月大幅度缩短至2024年的2.4个月。公司开发的智能排产系统将产能空置率大幅度降低，API设备的使用率从2020年的60%提升至1H25的72%。小分子和多肽生产的自动化率达到90%/80%，降低人工成本的同时显著提高了操作的准确性。精细化运营助力公司在面对宏观不确定性以及进行全球产能扩张的同时保持优秀的盈利水平。1H25公司的经调整毛利率和净利润率达到44.5%和30.4%，均为公司历史最高。管理层有信心保持有韧性的盈利能力。
    维持买入评级。小幅上调药明康德目标价至118.79元人民币（WACC：9.39%，永续增长率：2.0%），以反映全球早期研发需求改善的积极信号。我们预计公司在2025E/26E/27E持续经营收入同比增长16.0%/15.9%/15.8%，经调整non-IFRS净利润同比增长16.2%/17.6%/16.4%。